The purpose of this column is to highlight and summarize recent key patents in the pharmaceutical arena issued by the US Patent Office in April and May 2024.
Pharmaceutical Compositions Comprising Iodine and Steroid and Uses Thereof for Sinus Diseases;
B. Liang, B. Tessema, J.A. Capriotti, M.C. Samson, and W. Song; Iview Therapeutics, US; U.S. Patent # 11,986,491; May 21, 2024.
The reactivity of iodine with steroids is well-known. The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid for treating a clinical symptom in a patient’s airway (e.g., nose, lung, and sinus). The pharmaceutical compositions of this invention are stable, whether in solution, suspension, or dry powder state. Compositions disclosed above are also capable of eliminating biofilms without causing toxic inflammatory reactions in the sino-nasal tissues.
Micronized Eggshell Membrane Particles and the Use Thereof to Promote the Healing of Wounds;
R. Schmidt, H.P. Suso, and E. Kenny; Biovotec AS, Oslo, NO; U.S. Patent # 11,992,508; May 28, 2024.
Chronic wounds are defined as those which fail to heal or where there is excessive skin loss such as through burns. A major reason for the development of chronic wounds is an imbalance in the wound repair cycle. The present patent relates generally to the field of the treatment of wounds, specifically promoting healing. It uses eggshell membrane (ESM) microparticles and nanoparticles having a mean particle diameter of less than 100 nm. These particles display certain properties to promote chronic wound healing. The invention also provides pharmaceutical compositions, wound dressings, and implantable medical devices comprising the micronized ESM containing particles and methods for manufacturing the same.
Method for Coating Pharmaceutical Substrates;
P. Hoppu, T. Kaariainen, M.L. Kaariainen, and A. Turunen; Applied Materials, US; U.S. Patent # 11,986,559; May 21, 2024.
The current patent used atomic layer deposition technology to coat pharmaceutical substrates. This method can be used for the coating of small pharmaceutical particles and difficult, moisture-sensitive, and electrically charged pharmaceutical substrates. In this method, nano or microparticles are subjected to alternating surface reactions of at least a first and a second gaseous precursor by atomic layer deposition. The coating molecules can be an inorganic or organic material. The thickness of the coating layer can be from 1 nm to 100 nm.
Wearable Drug Delivery Device for Disease Management and System Therefore with Artificial Intelligence;
M. Sahani, A.D. Nguyen, A.A. Waitz, and L. C. Nguyen; Hana Patent Technology, US; U.S. Patent # 11,969,577: April 30, 2024.
This application is for a wearable delivery device for kidney disease management and a system with artificial intelligence. The device is designed to remotely administer a medication by a drug delivery device. The drug delivery device has one reservoir connected to a needle; one actuator to drive a fluid within a respective reservoir to the needle; a microcontroller to control the operation of the actuator; and a dosage control loop configured for communication with the microcontroller and a hemoglobin sensor. The dosage provided by the drug delivery device is automatically adjusted in response to the hemoglobin count sensed by the hemoglobin sensor for transdermal administration of medication for the management of chronic kidney disease.
Immunotherapy Against Several Tumors Including Gastrointestinal and Gastric Cancer;
J. Fritsche, T. Weinschenk, S. Walter, P. Lewandrowski, and H. Singh; Immatics Biotechnologies, GmbH, Tuebingen, DE; U.S. Patent # 11,957,730; April 16, 2024.
The present invention relates to the immunotherapy of cancer. It further relates to tumor-associated epitopes recognized by CD8+T cells. It relates to 33 novel peptide sequences and their variants derived from HLC class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. The patent claims a peptide consisting of amino acid sequence YVYQNNIYL (Seq ID # 66), which can bind to an MHC Class-I molecule, and this peptide is capable of being recognized by CD8 T cells.
Tumor Ablation Using Low-Intensity Ultrasound and Sound Excitable Drug;
C.H. Tung; Cornell University, US; U.S. Patent # 11,975,071; May 7, 2024.
Tumor ablation for conventional cancer treatment uses high-energy particles or waves, which are effective but associated with severe side effects. In particular, high-energy sources cause undesired damage to the tissues. This invention is directed to methods of ablating tumors using low-energy ultrasound and an excitable drug. The method is referred to as the sono-membrane rupture therapy (SMRT) method. In the SMRT method, a sound excitable drug (SED) that is non-cytotoxic to cells is used to disrupt the plasma membrane under gentle ultrasound insonation. The frequency and power density of insonation are within the physical therapy and medical imaging windows, thus the applied ultrasound is safe and not harmful to healthy tissues. The intruding SEDs weaken the membrane’s integrity. Under insonation, the ultrasound energy destabilized the SED-disrupted membranes, which results in membrane rupture and eventual cell death.
Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds;
S. M. Pham, J. Kankanala, J. Pettigrew, and C.P. Miller; Nuvation Bio Inc., US; U.S. Patent # 11,952,349; April 9, 2024.
PARP (poly ADP ribose polymerase) inhibitors are developed for multiple cancer indications. PARP agents prevent DNA repair leading to the death of cells and hence tumor inhibition. The inventors claimed compounds with the formula A-L-B. A group contained two chemical structures. There are several compounds in the L and B groups. The cancers that can be treated could be prostate, breast, triple-negative breast cancer, bladder, and liver cancer. These compounds can also be used to treat an estrogen and/or progesterone receptor over-expressing cancer or a glucocorticoid receptor over-expression cancer.
Author Details
Neelam Sharma, MS; Lakshmi Lavanya Kundurthy, BE; and Hemant N. Joshi, Ph.D., MBA*- Tara Innovations, LLC. www.tarainnovations.com *hemantjoshi.tara@gmail.com
Publication Details
This article appeared in American Pharmaceutical Review: Vol. 27, No. 5 July/Aug 2024Pages: 86-87
Subscribe to our e-newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!